IDXX (IDEXX Laboratories) Total Liabilities : $1,698 Mil (As of Dec. 2024)

View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Total Liabilities?

IDEXX Laboratories's Total Liabilities for the quarter that ended in Dec. 2024 was $1,698 Mil.

IDEXX Laboratories's quarterly Total Liabilities declined from Jun. 2024 ($1,834.61 Mil) to Sep. 2024 ($1,732.71 Mil) and declined from Sep. 2024 ($1,732.71 Mil) to Dec. 2024 ($1,698.13 Mil).

IDEXX Laboratories's annual Total Liabilities declined from Dec. 2022 ($2,138.03 Mil) to Dec. 2023 ($1,775.40 Mil) and declined from Dec. 2023 ($1,775.40 Mil) to Dec. 2024 ($1,698.13 Mil).

IDEXX Laboratories Total Liabilities Historical Data

The historical data trend for IDEXX Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Total Liabilities Chart

IDEXX Laboratories Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,661.77

1,747.21

2,138.03

1,775.40

1,698.13

IDEXX Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,775.40	1,784.61	1,834.61	1,732.71	1,698.13

IDEXX Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IDEXX Laboratories's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1067.916	+	(547.622	+	23.443
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	38.251	+	0	+	20.898)
	=	1,698

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3293.443	-	1595.313
	=	1,698

IDEXX Laboratories's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1067.916	+	(547.622	+	23.443
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	38.251	+	0	+	20.898)
	=	1,698

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	3293.443	-	1595.313
	=	1,698

IDEXX Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IDXX:Mexico 0J8P:UK IX1:Germany IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Executives

George Fennell	officer: CORPORATE VICE PRESIDENT	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak	director	C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sophie V. Vandebroek	director	6 OAK MEADOW ROAD, LINCOLN MA 01770
Bruce L. Claflin	director	7035 RIDGE ROAD, HANOVER MD 21076
James F Polewaczyk	officer: Corporate Vice President	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky	director, officer: President and CEO	ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers	director, officer: President & CEO	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt	director	CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Samer Abdul Samad	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Asha Collins	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lawrence D Kingsley	director	C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062